Lidocaína Aguettant (Lidocaine Hydrochloride)

Lidocaine works by reversibly binding to voltage‑gated sodium channels on nerve membranes, stabilizing them in an inactive state. This prevents sodium influx, blocking the generation and propagation of action potentials, which results in a localized loss of sensory perception without affecting surrounding tissues.

The dose of Lidocaína Aguettant is determined by the prescribing clinician based on factors such as the patient’s age, weight, overall health, the specific procedure, and the intended route of administration. Only a qualified health professional should set the appropriate dosage.

Safety data for lidocaine use during pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by the treating physician after a careful risk‑benefit assessment.

To order Lidocaína Aguettant, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lidocaine is an amide‑type local anesthetic with a rapid onset (1–2 minutes) and moderate duration (30–120 minutes) when used for infiltration. Compared with ester‑type agents such as procaine, lidocaine has a lower incidence of allergic reactions and a more predictable pharmacokinetic profile, making it a common first‑line choice for many minor procedures.

Lidocaína Aguettant should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the product from direct light and moisture. Do not freeze the solution, and keep it out of reach of children.

The solution is administered by a qualified health professional via injection into the target tissue. Depending on the clinical need, it can be given as an infiltration, intradermal or subcutaneous injection, using aseptic technique and appropriate needle size for the selected route.

Serious risks include cardiovascular collapse, severe hypotension, central nervous system toxicity (such as seizures or loss of consciousness), and allergic reactions that may progress to anaphylaxis. Immediate medical attention is required if any of these symptoms develop after administration.

Patients with a known hypersensitivity to lidocaine, other amide‑type local anesthetics, or any component of the formulation should not receive this product. It is also contraindicated in individuals with certain severe cardiac conduction disorders unless the benefits outweigh the risks as judged by a physician.